Marginal pulmonary function should not preclude lobectomy in selected patients with non–small cell lung cancer Matthew D. Taylor, MD, Damien J. LaPar,

Slides:

Advertisements

Similar presentations

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Advertisements

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Special Treatment Issues in Non-small Cell Lung Cancer

Stephen R. Broderick, MD, MPHS

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Lobar lung transplantation: One size fits all

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than.

Lung cancer screening: No more excuses

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Armin Kiankhooy, MD, Matthew D. Taylor, MD, Damien J

The effect of regionalization on outcome in pulmonary lobectomy: A Canadian national study Christian J. Finley, MD, MPH, Anna Bendzsak, MD, George Tomlinson,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Circulating tumor DNA: Solid data from liquid biopsies

Thoracic surgery education in Canada

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Utility of mediastinoscopy in clinical stage I lung cancers at risk for occult mediastinal nodal metastases Felix G. Fernandez, MD, Benjamin D. Kozower,

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Surgeons, valve repair in severely unbalanced atrioventricular septal defect, and the emperor's new clothes David M. Overman, MD The Journal of Thoracic.

The Society of Thoracic Surgeons General Thoracic Surgery Database: Establishing Generalizability to National Lung Cancer Resection Outcomes Damien J.

A bilobed thoracic outlet mass: Options for resection

Abbas Emaminia, MD, Sara A

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

Yang Zhang, MD, Haiquan Chen, MD, PhD

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Support Your Specialty

The search for the holy grail of lobectomy

It's not “just a shunt” but sometimes it should be…

Fixing the supply problem

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.

Military surgeons just want to have fun

Do we need a bibliometrician to know which way the wind is blowing?

A first start for lung transplantation?

Stephen R. Broderick, MD, MPHS

Derrick Y. Tam, MD, Stephen E. Fremes, MD, MSc

Frank C. Spencer, MD, FACS, pioneering cardiothoracic surgeon

Is endoluminal vacuum therapy “sponge worthy”?

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

Jeffrey H. Shuhaiber, MD, Jeff Moore, MS, David B. Dyke, MD

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Damien J. LaPar, MD, MSc, Gorav Ailawadi, MD, James M

Bicuspid aortopathy: Seeing the forest for the trees

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

After neoadjuvant chemoradiation therapy, predicted pulmonary function may be reduced by 10% Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular.

“The more things change…”: The challenges ahead

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

Aritoshi Hattori, MD, Kenji Suzuki, MD

More than vital: Who bears the burden?

Energized lung resections

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

American College of Cardiology/American Heart Association 2016 dual antiplatelet therapy (DAPT) focused update: Implications for surgeons Richard J.

Preoperative PFTs: The answer is blowing in the wind

Who should decide margin length in pulmonary excision of lung cancer?

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Journal changes and initiatives

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Presentation transcript:

Marginal pulmonary function should not preclude lobectomy in selected patients with non–small cell lung cancer Matthew D. Taylor, MD, Damien J. LaPar, MSc, MD, James M. Isbell, MD, MSCI, Benjamin D. Kozower, MD, MPH, Christine L. Lau, MD, MBA, David R. Jones, MD The Journal of Thoracic and Cardiovascular Surgery Volume 147, Issue 2, Pages 738-746 (February 2014) DOI: 10.1016/j.jtcvs.2013.09.064 Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 A, Risk-adjusted overall survival curve for American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021 trial or American College of Chest Physicians (ACCP) marginal-pulmonary function test (M-PFIT) criteria. B, Risk-adjusted overall survival curve for ACCP M-PFT criteria. The Journal of Thoracic and Cardiovascular Surgery 2014 147, 738-746DOI: (10.1016/j.jtcvs.2013.09.064) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions